Synergism of calycosin and bone marrow-derived mesenchymal stem cells to combat podocyte apoptosis to alleviate adriamycin-induced focal segmental glomerulosclerosis

Figure 4 Calycosin pretreatment enhances the ability of mesenchymal stem cells to ameliorate the injury of adriamycin-stimulated mouse podocyte cells in vitro. A: Podocin expression in each group as determined by immunofluorescence staining. Bar = 50 μm; B: Analysis of relative (podocin/GAPDH) mRNA expression by real-time quantitative polymerase chain reaction. Data are expressed as the mean ± SD (n = 3). ^bP < 0.001; C and D: Protein expression levels of podocin detected by Western blot and normalized to control. Data are expressed as the mean ± SD (n = 3). ^aP < 0.05, ^bP < 0.001. NC: Normal control; ADR: Adriamycin; MSCs: Mesenchymal stem cells; CA: Calycosin; MSCs^CA: Mesenchymal stem cells pretreated with calycosin.